This form contains the measure information submitted by stewards. Blank fields indicate no information was provided. Attachments also may have been submitted and are provided to reviewers. The subcriteria and most of the footnotes from the evaluation criteria are provided in Word comments within the form and will appear if your cursor is over the highlighted area. Hyperlinks to the evaluation criteria and ratings are provided in each section.

TAP/Workgroup (if utilized): Complete all yellow highlighted areas of the form. Evaluate the extent to which each subcriterion is met. Based on your evaluation, summarize the strengths and weaknesses in each section.

Note: If there is no TAP or workgroup, the SC also evaluates the subcriteria (yellow highlighted areas).

Steering Committee: Complete all pink highlighted areas of the form. Review the workgroup/TAP assessment of the subcriteria, noting any areas of disagreement; then evaluate the extent to which each major criterion is met; and finally, indicate your recommendation for the endorsement. Provide the rationale for your ratings.

Evaluation ratings of the extent to which the criteria are met
C = Completely (unquestionably demonstrated to meet the criterion)
P = Partially (demonstrated to partially meet the criterion)
M = Minimally (addressed BUT demonstrated to only minimally meet the criterion)
N = Not at all (NOT addressed; OR incorrectly addressed; OR demonstrated to NOT meet the criterion)
NA = Not applicable (only an option for a few subcriteria as indicated)

(for NQF staff use) NQF Review #: 0162 NQF Project: Cardiovascular Endorsement Maintenance 2010

MEASURE DESCRIPTIVE INFORMATION

De.1 Measure Title: ACEI or ARB for left ventricular systolic dysfunction - Heart Failure (HF) Patients

De.2 Brief description of measure: Percentage of heart failure (HF) patients with left ventricular systolic dysfunction (LVSD) who are prescribed an ACEI or ARB at hospital discharge. For purposes of this measure, LVSD is defined as chart documentation of a left ventricular ejection fraction (LVEF) less than 40% or a narrative description of left ventricular systolic (LVS) function consistent with moderate or severe systolic dysfunction.

1.1-2 Type of Measure: Process

De.3 If included in a composite or paired with another measure, please identify composite or paired measure N/A

De.4 National Priority Partners Priority Area: Population health
De.5 IOM Quality Domain: Effectiveness
De.6 Consumer Care Need: Living with illness

CONDITIONS FOR CONSIDERATION BY NQF

Four conditions must be met before proposed measures may be considered and evaluated for suitability as voluntary consensus standards:

A. The measure is in the public domain or an intellectual property (measure steward agreement) is signed. Public domain only applies to governmental organizations. All non-government organizations must sign a measure steward agreement even if measures are made publicly and freely available.

A.1 Do you attest that the measure steward holds intellectual property rights to the measure and the right to use aspects of the measure owned by another entity (e.g., risk model, code set)? Yes

A.2 Indicate if Proprietary Measure (as defined in measure steward agreement):

A.3 Measure Steward Agreement: Government entity and in the public domain - no agreement necessary

A.4 Measure Steward Agreement attached:

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable
B. The measure owner/steward verifies there is an identified responsible entity and process to maintain and update the measure on a schedule that is commensurate with the rate of clinical innovation, but at least every 3 years.  Yes, information provided in contact section

| C. The intended use of the measure includes both public reporting and quality improvement. |
| Purpose: Public reporting, Internal quality improvement |
| Accountability, Payment incentive |

| D. The requested measure submission information is complete. Generally, measures should be fully developed and tested so that all the evaluation criteria have been addressed and information needed to evaluate the measure is provided. Measures that have not been tested are only potentially eligible for a time-limited endorsement and in that case, measure owners must verify that testing will be completed within 12 months of endorsement. |
| Testing: Yes, fully developed and tested |
| Have NQF-endorsed measures been reviewed to identify if there are similar or related measures? Yes |

(for NQF staff use) Have all conditions for consideration been met? Met

Staff Notes to Steward (if submission returned):

Staff Notes to Reviewers (issues or questions regarding any criteria): Rate of exclusion for LVEF not being measured is 51%.

Staff Reviewer Name(s): RWinkler

TAP/Workgroup Reviewer Name:

Steering Committee Reviewer Name:

1. IMPORTANCE TO MEASURE AND REPORT

Extent to which the specific measure focus is important to making significant gains in health care quality (safety, timeliness, effectiveness, efficiency, equity, patient-centeredness) and improving health outcomes for a specific high impact aspect of healthcare where there is variation in or overall poor performance. Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria.  (evaluation criteria)

1a. High Impact

(for NQF staff use) Specific NPP goal:

1a.1 Demonstrated High Impact Aspect of Healthcare: Affects large numbers, Leading cause of morbidity/mortality, Severity of illness, Patient/societal consequences of poor quality

1a.2 Summary of Evidence of High Impact: Heart failure (HF) is a major and growing public health problem in the United States that currently affects approximately 5.7 million Americans. More than 670,000 persons in the US are diagnosed with HF annually, and a person aged 40 years or older has a 1 in 5 chance of developing HF in their lifetime. HF is primarily a disease of the elderly, affecting more than 1 in 100 persons older than 65 years. HF is noted as the underlying cause of almost 59,000 deaths in the US annually, and the 5-year case fatality rate approaches 50%. HF was also responsible for more than 1 million hospitalizations and nearly 3.4 million ambulatory care visits in the US in 2006. Hospital discharges for HF increased by 126% between 1996 and 2006. It is the leading cause of hospitalization in persons older than 65 years. The estimated direct and indirect costs of HF in the United States for 2009, including inpatient and outpatient costs, were $37.2 billion.

### 1c.2-3. Healthcare services/care processes influence the outcome post-MI. Benefits of ACE inhibition were seen in patients with mild, moderate, or severe symptoms and in benefits of ACE-inhibitors on morbidity and mortality in HF patients with reduced LVEF, both chronically and system (RAAS) in all HF patients with reduced LVEF. Several large clinical trials have demonstrated in the benefits of ACE-inhibitors on morbidity and mortality in HF patients with reduced LVEF, both chronically and post-MI. Benefits of ACE inhibition were seen in patients with mild, moderate, or severe symptoms and in

<table>
<thead>
<tr>
<th>Rating</th>
<th>C</th>
<th>P</th>
<th>M</th>
<th>N</th>
<th>NA</th>
<th>1b. Opportunity for Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>1b.1</td>
<td>B</td>
<td>P</td>
<td>M</td>
<td>N</td>
<td></td>
<td>Benefits (improvements in quality) envisioned by use of this measure: Use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers in patients with left ventricular systolic dysfunction significantly reduces mortality and other adverse outcomes. Hospital performance rates have gradually increased over the years this measure has been reported to the public. Providers understand the importance of prescribing ACEIs and ARBs for their HF patients with LVSD unless contraindications exist. Ongoing use of this measure will help ensure that high performing providers maintain high performance and the relatively lower performing providers have an impetus to improve.</td>
</tr>
<tr>
<td>1b.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Summary of data demonstrating performance gap (variation or overall poor performance) across providers: National performance rates: 2Q09: 93.8% 3Q09: 93.6% 4Q09: 94.3% 1Q10: 94.7%</td>
</tr>
<tr>
<td>1b.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Citations for data on performance gap: Clinical warehouse data: 2Q09: 66,437 HF patients, 3,709 hospitals 3Q09: 59,825 HF patients, 3,622 hospitals 4Q09: 64,433 HF patients, 3,689 hospitals 1Q10: 67,827 HF patients, 3,724 hospitals</td>
</tr>
<tr>
<td>1b.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Summary of Data on disparities by population group: At the univariate analysis level (unadjusted odds ratios) and consistent with findings in our other HF measures, one racial/ethnic group, namely Native American, had a lower rate in this measure (91.8%) compared to the other racial/ethnic groups (Caucasian 93.1%, African-American 95.1%, Hispanic 93.5%, and Asian/Pacific Islander 95.3%).</td>
</tr>
<tr>
<td>1b.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Citations for data on Disparities: 2009 Clinical warehouse data (Total 250,713 patients with race not missing): 155,808 Caucasian patients, 69,597 African-American patients, 20,068 Hispanic patients, 3,962 Asian/Pacific Islander patients, and 1,278 Native American patients.</td>
</tr>
</tbody>
</table>

### 1c. Outcome or Evidence to Support Measure Focus

<table>
<thead>
<tr>
<th>Rating</th>
<th>C</th>
<th>P</th>
<th>M</th>
<th>N</th>
<th>NA</th>
<th>1c.1 Relationship to Outcomes (For non-outcome measures, briefly describe the relationship to desired outcome. For outcomes, describe why it is relevant to the target population): ACE inhibitors reduce mortality and morbidity in patients with heart failure and left ventricular systolic dysfunction and are effective in a wide range of patients. Additional benefits of ACEIs include alleviation of symptoms. Clinical trials have established ARB therapy as an acceptable alternative to ACEI, especially in patients who are ACEI intolerant. National guidelines strongly recommend ACEIs for patients hospitalized with heart failure. Guideline committees have also supported the inclusion of ARBs in performance measures for heart failure.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1c.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. Type of Evidence: Evidence-based guideline, Randomized controlled trial, Systematic synthesis of research, Meta-analysis</td>
</tr>
</tbody>
</table>
| 1c.4   |   |   |   |    |    | Summary of Evidence (as described in the criteria; for outcomes, summarize any evidence that healthcare services/care processes influence the outcome): There is compelling evidence that ACE inhibitors should be used to inhibit the renin-angiotensin-aldosterone system (RAAS) in all HF patients with reduced LVEF. Several large clinical trials have demonstrated in the benefits of ACE-inhibitors on morbidity and mortality in HF patients with reduced LVEF, both chronically and post-MI. Benefits of ACE inhibition were seen in patients with mild, moderate, or severe symptoms and in

*Comment [k3]: Examples of data on opportunity for improvement include, but are not limited to: prior studies, epidemiologic data, measure data from pilot testing or implementation. If data are not available, the measure focus is systematically assessed (e.g., expert panel rating) and judged to be a quality problem.*
patients with or without coronary artery disease. Angiotensin converting enzyme inhibitors remain the first choice for inhibition of the renin-angiotensin system in chronic HF, but ARBs should be considered a reasonable alternative for patients unable to tolerate ACEIs because of cough. The ARBs valsartan and candesartan have demonstrated the benefit of reducing hospitalizations and mortality in patients with LVSD. Additionally, ARBs are generally well tolerated in randomized trials of patients judged to be intolerant of ACE inhibitors.

1c.5 Rating of strength/quality of evidence (also provide narrative description of the rating and by whom):

[ACCF/AHA]: Level of Evidence A (Data derived from multiple randomized trials or meta-analyses, Multiple populations evaluated, References used to determine level of evidence must be provided and cited with the recommendation.). [HFSA]: Strength of Evidence A (Randomized, controlled, clinical trials; May be assigned based on results of a single trial).

1c.6 Method for rating evidence: [ACCF/AHA]

The methodology used by the ACCF/AHA Task Force on Practice Guidelines is fully documented in their publication “Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines” (http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf). The guidelines are based upon a comprehensive assessment, both electronic and manual, of the English-language medical literature. This search focuses on high-quality randomized controlled trials, meta-analyses and systematic reviews, and when applicable observational studies. In some cases where higher quality data is not available, observational studies and case series are also considered. The quality of the design and execution of these studies is determined. When appropriate, data tables are generated from the available literature. After a review of the available literature, the writing committee rates the evidence according to the schemes outlined in their publication.

[HFSA]

- Strength of Evidence A - Randomized, Controlled, Clinical Trials; May be assigned based on results of a single trial: Randomized controlled clinical trials provide what is considered the most valid form of guideline evidence. Some guidelines require at least 2 positive randomized clinical trials before the evidence for a recommendation can be designated level A. The HFSA guideline committee has occasionally accepted a single randomized, controlled, outcome-based clinical trial as sufficient for level A evidence when the single trial is large with a substantial number of endpoints and has consistent and robust outcomes. However, randomized clinical trial data, whether derived from one or multiple trials, have not been taken simply at face value. They have been evaluated for: (1) endpoints studied, (2) level of significance, (3) reproducibility of findings, (4) generalizability of study results, and (5) sample size and number of events on which outcome results are based.

- Strength of Evidence B - Cohort and Case-Control Studies; Post hoc, subgroup analysis, and meta-analysis; Prospective observational studies or registries: The HFSA guideline process also considers evidence arising from cohort studies or smaller clinical trials with physiologic or surrogate endpoints. This level B evidence is derived from studies that are diverse in design and may be prospective or retrospective in nature. They may involve subgroup analyses of clinical trials or have a case control or propensity design using a matched subset of trial populations. Dose-response studies, when available, may involve all or a portion of the clinical trial population. Evidence generated from these studies has well-recognized, inherent limitations. Nevertheless, their value is enhanced through attention to factors such as pre-specification of hypotheses, biologic rationale, and consistency of findings between studies and across different populations.

- Strength of Evidence C - Expert Opinion; Observational studies-epidemiologic findings; Safety Reporting from large-scale use in practice: The present HFSA guideline makes extensive use of expert opinion, or C-level evidence. The need to formulate recommendations based on level C evidence is driven primarily by a paucity of scientific evidence in many areas critical to a comprehensive guideline. For example, the diagnostic process and the steps used to evaluate and monitor patients with established HF have not been the subject of clinical studies that formally test the validity of one approach versus another. In areas such as these, recommendations must be based on expert opinion or go unaddressed.

1c.7 Summary of Controversy/Contradictory Evidence: Aside from avoiding use in patients with clear contraindications to ACEI or ARB therapy, there is broad support in existing guidelines for the use of ACEI/ARBs in reducing mortality and morbidity.

1c.8 Citations for Evidence (other than guidelines): · Packer M, Cohn J. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve
outcomes nationwide in heart failure. Am J Cardiol 1999;83:1A-38A.


1c.9 Quote the Specific guideline recommendation (including guideline number and/or page number):

[ACCF/AHA]

3 (under class I). Angiotensin-converting enzyme inhibitors are recommended for all patients with current or prior symptoms of HF and reduced LVEF, unless contraindicated. [p. 1353]

5. Angiotensin II receptor blockers are recommended in patients with current or prior symptoms of HF and reduced LVEF who are ACE inhibitor-intolerant. [p. 1353]

[HFSA]

5.5 ACE inhibitor therapy is recommended for asymptomatic patients with reduced LVEF (<40%). [p. 485]

7.1 ACE inhibitors are recommended for routine administration to symptomatic and asymptomatic patients with LVEF < 40%. [p. 487]

7.3 ARBs are recommended for routine administration to symptomatic and asymptomatic patients with an LVEF < 40% who are intolerant to ACE inhibitors for reasons other than hyperkalemia or renal insufficiency. [p. 487]

1c.10 Clinical Practice Guideline Citation:


1c.11 National Guideline Clearinghouse or other URL:


http://content.onlinejacc.org/cgi/reprint/53/15/1343.pdf

1c.12 Rating of strength of recommendation (also provide narrative description of the rating and by whom):

[ACCF/AHA]: [3. and 5.] Class I recommendations - Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective. Benefit >> Risk. Procedure/treatment should be performed/administered.

Class IIa recommendation - Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment. Weight of evidence/opinion is in favor of usefulness/efficacy. Benefit >> Risk. It is reasonable to perform procedure/administer treatment. [HFSA]: Strength of recommendation - "Is recommended": The recommended therapy or management process should be followed as often as possible in individual patients (part of routine care).
1c.13 Method for rating strength of recommendation (if different from USPSTF system, also describe rating and how it relates to USPSTF):


[HFSA] There are several degrees of favorable recommendations and a single category for therapies felt to be not effective.
- “Is recommended”: The recommended therapy or management process should be followed as often as possible in individual patients (part of routine care). Exceptions are carefully delineated and should be minimized.
- “Should be considered”: A majority of patients should receive the intervention, with some discretion involving individual patients.
- “May be considered”: Individualization of therapy is indicated.
- “Is not recommended”: Therapeutic intervention should not be used.

Both the ACCF/AHA Guidelines and the USPSTF assess evidence with respect to two parameters: 1) the magnitude of the benefit, and 2) the certainty of this benefit. However, they use different coding systems. In ascertaining magnitude of the benefit, the ACCF/AHA uses a Class I-III scale and the USPSTF uses a high-moderate-low scale. In determining the certainty of this benefit, the ACCF/AHA uses levels of evidence A-C and USPSTF uses a high-moderate-low scale. The HFSA guidelines also characterize their recommendations according to both the weight of evidence (on an A, B, C scale) as well as the strength of the recommendation (categorized as “is recommended,” “should be considered,” “may be considered,” and “is not recommended”).

1c.14 Rationale for using this guideline over others:
The ACCF/AHA and HFSA guidelines are the only national guidelines that address the therapy of patients with HF; they use an explicit and transparent methodology; and have thus served as the foundation of national quality metrics.

TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Importance to Measure and Report?

Steering Committee: Was the threshold criterion, Importance to Measure and Report, met?

Rationale: Yes

1 2. SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (evaluation criteria)

2a. MEASURE SPECIFICATIONS

Do you have a web page where current detailed measure specifications can be obtained?

S.1 Yes, provide web page URL:

2a. Precisely Specified

2a.1 Numerator Statement (Brief, text description of the numerator - what is being measured about the target population, e.g. target condition, event, or outcome):

HF patients who are prescribed an ACEI or ARB at hospital discharge

2a.2 Numerator Time Window (The time period in which cases are eligible for inclusion in the numerator):

From hospital arrival to time of hospital discharge

2a.3 Numerator Details (All information required to collect/calculate the numerator, including all codes, units, and definitions):

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable
**Denominator Statement (Brief, text description of the denominator - target population being measured):**

HF patients (International Classification of Diseases, 9th revision, Clinical Modification [ICD-9-CM] principal diagnosis code of HF: 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43, 428.9); with chart documentation of a left ventricular ejection fraction (LVEF) < 40% or a narrative description of left ventricular systolic (LVS) function consistent with moderate or severe systolic dysfunction.

**Target population gender:** Female, Male

**Target population age range:** Greater than or equal to 18 years old

**Denominator Time Window (The time period in which cases are eligible for inclusion in the denominator):**

From hospital arrival to time of hospital discharge.

**Denominator Details (All information required to collect/calculate the denominator - the target population being measured - including all codes, logic, and definitions):**

<table>
<thead>
<tr>
<th>ICD-9-CM Principal Diagnosis codes:</th>
</tr>
</thead>
<tbody>
<tr>
<td>402.01: Hypertensive heart disease, malignant, with heart failure</td>
</tr>
<tr>
<td>402.11: Hypertensive heart disease, benign, with heart failure</td>
</tr>
<tr>
<td>402.91: Hypertensive heart disease, unspecified, with heart failure</td>
</tr>
<tr>
<td>404.01: Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified</td>
</tr>
<tr>
<td>404.03: Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease</td>
</tr>
<tr>
<td>404.11: Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified</td>
</tr>
<tr>
<td>404.13: Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease</td>
</tr>
<tr>
<td>404.91: Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified</td>
</tr>
<tr>
<td>404.93: Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease</td>
</tr>
<tr>
<td>428.0: Congestive heart failure, unspecified</td>
</tr>
<tr>
<td>428.1: Left heart failure</td>
</tr>
<tr>
<td>428.20: Unspecified systolic heart failure</td>
</tr>
<tr>
<td>428.21: Acute systolic heart failure</td>
</tr>
<tr>
<td>428.22: Chronic systolic heart failure</td>
</tr>
<tr>
<td>428.23: Acute on chronic systolic heart failure</td>
</tr>
<tr>
<td>428.30: Unspecified diastolic heart failure</td>
</tr>
<tr>
<td>428.31: Acute diastolic heart failure</td>
</tr>
<tr>
<td>428.32: Chronic diastolic heart failure</td>
</tr>
<tr>
<td>428.33: Acute on chronic diastolic heart failure</td>
</tr>
<tr>
<td>428.40: Unspecified combined systolic and diastolic heart failure</td>
</tr>
<tr>
<td>428.41: Acute combined systolic and diastolic heart failure</td>
</tr>
<tr>
<td>428.42: Chronic combined systolic and diastolic heart failure</td>
</tr>
<tr>
<td>428.43: Acute on chronic combined systolic and diastolic heart failure</td>
</tr>
<tr>
<td>428.9: Heart failure, unspecified</td>
</tr>
</tbody>
</table>
**2a.9 Denominator Exclusions** *(Brief text description of exclusions from the target population):* Exclusions:

- Patients who had a left ventricular assistive device (LVAD) or heart transplant procedure during hospital stay (ICD-9-CM procedure code of LVAD or Heart Transplant: 33.6, 37.51, 37.52, 37.53, 37.54, 37.60, 37.62, 37.63, 37.65, 37.66, 37.68)
- <18 years of age
- Discharged to another hospital
- Expired
- Left against medical advice
- Discharged to home for hospice care
- Discharged to a health care facility for hospice care
- Patients enrolled in clinical trials
- Patients with comfort measures only documented
- Patients with a documented reason for no ACEI and no ARB at discharge

**2a.10 Denominator Exclusion Details** *(All information required to collect exclusions to the denominator, including all codes, logic, and definitions)*:

Refer to http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228760129036:
- Section 1 - Data Dictionary | Alphabetical Data Dictionary - pages 1-257 through 1-260.
- Appendices | Appendix C - Medication Tables PDF - pages Appendix C-6 through Appendix C-7 plus pages Appendix C-11 through Appendix C-12, and Appendix H - Miscellaneous Tables - page Appendix H-5.
- Section 2 - Measurement Information | Section 2.2 - Heart Failure (HF) - pages HF-5 plus HF-3-1 through HF-3-5.

**2a.11 Stratification Details/Variables** *(All information required to stratify the measure including the stratification variables, all codes, logic, and definitions)*: N/A

**2a.12-13 Risk Adjustment Type:** No risk adjustment necessary

**2a.14 Risk Adjustment Methodology/Variables** *(List risk adjustment variables and describe conceptual models, statistical models, or other aspects of model or method)*: N/A

**2a.15-17 Detailed risk model available Web page URL or attachment:**

**2a.18-19 Type of Score:** Rate/proportion

**2a.20 Interpretation of Score:** Better quality = Higher score

**2a.21 Calculation Algorithm** *(Describe the calculation of the measure as a flowchart or series of steps)*:

Refer to http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228760129036: Section 2 - Measurement Information | Section 2.2 - Heart Failure (HF) - pages HF-5 plus HF-3-4 through HF-3-5.

**2a.22 Describe the method for discriminating performance (e.g., significance testing):**

Benchmarks are established using the ABC methodology, based on the actual performance of the top facilities. ABC benchmarks identify superior performance and encourage poorer performers to improve. The methodology is a data-driven, peer-group performance feedback used to positively affect outcomes.

**2a.23 Sampling (Survey) Methodology** *(If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate)*:

Patients admitted to the hospital for inpatient acute care with an ICD-9-CM Principal Diagnosis Code for HF as

---

**Comment [k9]:** 11 Risk factors that influence outcomes should not be specified as exclusions.

12 Patient preference is not a clinical exception to eligibility and can be influenced by provider interventions.
defined in section 2a.8, no ICD-9-CM Principal or Other Procedure Code of Left Ventricular Assistive Device (LVAD) or Heart Transplant as defined in section 2a.9, patient age greater than or equal to 18 years, and a length of stay less than or equal to 120 days would be included in the initial patient population and eligible to be sampled.

Monthly Sample Size Based on Population Size (Average monthly initial patient population size: Minimum required sample size):

- >= 506: 102
- 131-505: 20% of Initial Patient Population size
- 26-130: 26
- < 26: 100%

2a.24 Data Source (Check the source(s) for which the measure is specified and tested)

- Paper medical record/flow-sheet, Electronic Health/Medical Record

2a.25 Data source/data collection instrument (identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.):

- Centers for Medicare & Medicaid Services (CMS) Abstraction & Reporting Tool (CART), Vendor tools also available.


2a.32-35 Level of Measurement/Analysis (Check the level(s) for which the measure is specified and tested)

- Facility/Agency, Population: national, Program: QIO

2a.36-37 Care Settings (Check the setting(s) for which the measure is specified and tested)

- Hospital

2a.38-41 Clinical Services (Healthcare services being measured, check all that apply)

TESTING/ANALYSIS

2b. Reliability testing

2b.1 Data/sample (description of data/sample and size):

- CDAC (Clinical Data Abstraction Center) validation sample: 3Q09

2b.2 Analytic Method (type of reliability & rationale, method for testing):

- CDAC validation sampling involves SDPS selection of sample of 5 cases/quarter across all topics (AMI, HF, Pneumonia, etc.) from each hospital with a minimum of 6 discharges (across all topics) in the Clinical Data Warehouse within 4 months + 15 days following 3Q09. Hospital-abstracted data is compared to CDAC-adjudicated data.

2b.3 Testing Results (reliability statistics, assessment of adequacy in the context of norms for the test conducted):

- ACEI Prescribed at Discharge - 91.0%
- ARB Prescribed at Discharge - 86.4%
- Clinical Trial - 98.9%
- Comfort Measures Only - 94.3%
- LVSD - 94.7%
- Reason for No ACEI and No ARB at Discharge - 77.5%

2c. Validity testing

Comment [KP10]: 2b. Reliability testing demonstrates the measure results are repeatable, producing the same results a high proportion of the time when assessed in the same population in the same time period.

Comment [k11]: 8 Examples of reliability testing include, but are not limited to: inter-rater/abstractor or intra-rater/abstractor studies; internal consistency for multi-item scales; test-retest for survey items. Reliability testing may address the data items or final measure score.

Comment [KP12]: 2c. Validity testing demonstrates that the measure reflects the quality of care provided, adequately distinguishing good and poor quality. If face validity is the only validity addressed, it is systematically assessed.

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable
### 2c. Data/sample (description of data/sample and size):

Face validity is regularly assessed with the Technical Expert Panel responsible for reviewing and supporting the measure topic.

### 2c.2 Analytic Method (type of validity & rationale, method for testing):

Face validity

### 2c.3 Testing Results (statistical results, assessment of adequacy in the context of norms for the test conducted):

N/A

### 2d. Exclusions Justified

#### 2d.1 Summary of Evidence supporting exclusion(s):

The exclusions of age < 18 years, length of stay > 120 days, and enrollment in a clinical trial are common to the other measures in the HF measure set, and to the inpatient Hospital Inpatient Quality Reporting Program measure set in general. Patients with documented comfort measures only or those discharged to hospice are appropriate exclusions, as the goal in these cases is palliative care - Therefore, the non-use of ACEI/ARB is often clinically appropriate. In relation to the exclusion of LVAD and heart transplant cases, there is no clinical data to support the use of ACE-inhibitors in this specific population. Patients who leave against medical advice or who expire are appropriately excluded, and it is sensible for those who are discharged to another hospital (where the patient goes on to continue acute care treatment) to be omitted as well. Lastly, there are clinically important contraindications to the use of ACEIs or ARBs. Reasons vary, from patient refusal and ACEI/ARB allergies, to clinical conditions such as moderate or severe aortic stenosis or severe hypotension. In these types of cases, the non-use of ACEI/ARB should not count against the provider if the clinical reason for not prescribing the ACEI/ARB is documented. Exclusions in this measure are concordant with both the 2005 ACC/AHA Clinical Performance Measures for Adults With Chronic Heart Failure and the 2010 ACC/AHA/PCPI Heart Failure Performance Measure Set.

#### 2d.2 Citations for Evidence:


#### 2d.3 Data/sample (description of data/sample and size):

Clinical warehouse data: 245,779 HF patients, 4,116 hospitals, 1Q10.

#### 2d.4 Analytic Method (type analysis & rationale):

A frequency count was conducted to calculate the percentages outlined in section 2d.5. Frequency counts are a simple, efficient way to determine the occurrence of specific values of a data element in a given data set.

#### 2d.5 Testing Results (e.g., frequency, variability, sensitivity analyses):

**Rates of Exclusion:**

- Patients with comfort measures only documented: 2.7%
- Patients enrolled in clinical trials: 0.2%
- Discharged/transferred to another hospital for inpatient care, discharged/transferred to a federal health care facility, discharged/transferred to hospice, expired, or left against medical advice or discontinued care: 10.1%
- LVSD not documented as either EF < 40% or a narrative description consistent with moderate or severe systolic dysfunction: 51.1%
- Patients with a documented reason for no ACEI and no ARB at discharge: 8.3%

### 2e. Risk Adjustment for Outcomes/Resource Use Measures

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable
2f. Identification of Meaningful Differences in Performance

2f.1 Data/sample from Testing or Current Use (description of data/sample and size): Clinical warehouse data.

- Q2Q9: 66,437 HF patients, 3,709 hospitals
- Q3Q9: 59,825 HF patients, 3,622 hospitals
- Q4Q9: 64,433 HF patients, 3,709 hospitals
- Q1Q0: 67,827 HF patients, 3,724 hospitals

2f.2 Methods to identify statistically significant and practically/meaningfully differences in performance (type of analysis & rationale):

Analysts review quarterly benchmarks established (using the ABC methodology) and trends to identify differences in performance scores and investigate the possible causes. ABC benchmarks identify superior performance and encourage poorer performers to improve. The methodology is data-driven, peer-group performance feedback used to positively affect outcomes. If measure specifications (algorithms, data elements) are found to cause the difference in performance, they are reviewed for possible updates.

2f.3 Provide Measure Scores from Testing or Current Use (description of scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance):

- National performance rates:
  - Q2Q9: 93.8% (benchmark 99.8%)
  - Q3Q9: 93.6% (benchmark 99.8%)
  - Q4Q9: 94.3% (benchmark 99.8%)
  - Q1Q0: 94.7% (benchmark 99.8%)

2g. Comparability of Multiple Data Sources/Methods

2g.1 Data/sample (description of data/sample and size): Both paper records and electronic health records can be used to collect data. Some allowances have been made as facilities incorporate EHRs in their facilities because vendors do not utilize identical data fields, but customize products according to facility need and preferences.

2g.2 Analytic Method (type of analysis & rationale):

No tests have been performed on this measure to determine comparability of sources (paper medical record vs. EHR).

2g.3 Testing Results (e.g., correlation statistics, comparison of rankings):

N/A

2h. Disparities in Care

2h.1 If measure is stratified, provide stratified results (scores by stratified categories/cohorts): Not stratified, but results according to race, sex, etc can be determined.

2h.2 If disparities have been reported/identified, but measure is not specified to detect disparities, provide follow-up plans:

Although preliminary univariate analyses suggested a possible disparity (as described in 1b.4), further analyses are needed to control for the simultaneous effect of other potential factors such as age, gender,
comorbidity, and hospital characteristics and to take into account the correlation/cluster effect of patients discharged from the same hospitals.

TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Scientific Acceptability of Measure Properties?

Steering Committee: Overall, to what extent was the criterion, Scientific Acceptability of Measure Properties, met?

### 3. USABILITY

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (evaluation criteria)

#### 3a. Meaningful, Understandable, and Useful Information

3a.1 Current Use: In use

3a.2 Use in a public reporting initiative (disclosure of performance results to the public at large) (If used in a public reporting initiative, provide name of initiative(s), locations, Web page URL(s). If not publicly reported, state the plans to achieve public reporting within 3 years);
Hospital Inpatient Quality Reporting Program:

- [http://www.hospitalcompare.hhs.gov/](http://www.hospitalcompare.hhs.gov/)

3a.3 If used in other programs/initiatives (If used in quality improvement or other programs/initiatives, name of initiative(s), locations, Web page URL(s). If not used for QI, state the plans to achieve use for QI within 3 years);
Hospital Inpatient Quality Reporting Program (Measures can be used by individual hospitals for internal quality improvement):

- [http://www.hospitalcompare.hhs.gov/](http://www.hospitalcompare.hhs.gov/)
Additionally, the Joint Commission also uses this measure for accreditation.

Testing of Interpretability  (Testing that demonstrates the results are understood by the potential users for public reporting and quality improvement)

3a.4 Data/sample (description of data/sample and size): Unknown. [Feedback on the Hospital Compare website (used for public reporting) is collected through another contractor.]

3a.5 Methods (e.g., focus group, survey, QI project):
Voluntary electronic survey by visitors to website.

3a.6 Results (qualitative and/or quantitative results and conclusions):
Not available.

3b/3c. Relation to other NQF-endorsed measures

3b.1 NQF # and Title of similar or related measures:
NQF #0610: Heart Failure - Use of ACE Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) Therapy

(for NQF staff use) Notes on similar/related endorsed or submitted measures:

3b. Harmonization
If this measure is related to measure(s) already endorsed by NQF (e.g., same topic, but different target population-setting/data source or different topic but same target population):

Comment [KP22]: 3a. Demonstration that information produced by the measure is meaningful, understandable, and useful to the intended audience(s) for both public reporting (e.g., focus group, cognitive testing) and informing quality improvement (e.g., quality improvement initiatives). An important outcome that may not have an identified improvement strategy still can be useful for informing quality improvement by identifying the need for and stimulating new approaches to improvement.

Comment [KP23]: 3b. The measure specifications are harmonized with other measures, and are applicable to multiple levels and settings.
<table>
<thead>
<tr>
<th>3b.2 Are the measure specifications harmonized? If not, why?</th>
</tr>
</thead>
<tbody>
<tr>
<td>No, this measure’s specifications are not harmonized with NQF #0610 measure specifications. NQF #0610 is an outpatient measure which uses a three year time window and is based on administrative data. In contrast, this measure is concentrated on care of the HF patient who is admitted for inpatient care; a completely different focus in terms of setting and care. NQF #0092 appears to use the same ICD-9-CM codes to identify HF patients as this measure, and like this measure, excludes patients with aortic stenosis and ACEI/ARB allergies, but it automatically excludes many other types of patients, including but not limited to those with hyperpotassemia, secondary renovascular hypertension, chronic kidney disease, multiple myeloma, hypertrophic cardiomyopathy, pregnancy, pulmonary hypertension treatment, hydralazine after prior ACEI/ARB use, and evidence of metastatic disease or active treatment of malignancy in the last 6 months. Conditions which our team believes are relative contraindications which require that the physician specifically document a linkage to the non-use of ACEI/ARB (vs. automatic exclusion).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3c. Distinctive or Additive Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>3c.1 Describe the distinctive, improved, or additive value this measure provides to existing NQF-endorsed measures:</td>
</tr>
<tr>
<td>3c.2 No NQF-endorsed measures with same topic and target population.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5.1 If this measure is similar to measure(s) already endorsed by NQF (i.e., on the same topic and the same target population), Describe why it is a more valid or efficient way to measure quality:</th>
</tr>
</thead>
<tbody>
<tr>
<td>No NQF-endorsed measures with same topic and target population.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Usability?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steering Committee: Overall, to what extent was the criterion, Usability, met?</td>
</tr>
<tr>
<td>Rationale:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. FEASIBILITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4a. Data Generated as a Byproduct of Care Processes</th>
</tr>
</thead>
<tbody>
<tr>
<td>4a.1-2 How are the data elements that are needed to compute measure scores generated?</td>
</tr>
<tr>
<td>Data generated as byproduct of care processes during care delivery (Data are generated and used by healthcare personnel during the provision of care, e.g., blood pressure, lab value, medical condition), Coding/abstraction performed by someone other than person obtaining original information (E.g., DRG, ICD-9 codes on claims, chart abstraction for quality measure or registry)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4b. Electronic Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>4b.1 Are all the data elements available electronically? (elements that are needed to compute measure scores are in defined, computer-readable fields, e.g., electronic health record, electronic claims)</td>
</tr>
<tr>
<td>4b.2 If not, specify the near-term path to achieve electronic capture by most providers. Retooling work with HHS is expected to be completed in the near future.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4c. Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>4c.1 Do the specified exclusions require additional data sources beyond what is required for the numerator and denominator specifications?</td>
</tr>
<tr>
<td>4c.2 If yes, provide justification.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4d. Susceptibility to Inaccuracies, Errors, or Unintended Consequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>If this measure is similar to measure(s) already endorsed by NQF (i.e., on the same topic and the same target population), Describe why it is a more valid or efficient way to measure quality:</td>
</tr>
<tr>
<td>No NQF-endorsed measures with same topic and target population.</td>
</tr>
</tbody>
</table>
4d.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measure and describe how these potential problems could be audited. If audited, provide results.

1. Documentation of both a reason for not prescribing an ACEI and reason for not prescribing an ARB are required for measure exclusion (barring other exclusions). Providers challenged the need to explicitly document both a reason for not prescribing an ACEI and reason for not prescribing an ARB when the reasons for not prescribing one class often apply to the other class in many cases. This concern was rectified in the measure and abstraction specifications effective with April 1, 2007 discharges. Specifications were changed to allow documentation of a reason for not prescribing one class (either ACEI or ARB) to be considered implicit documentation of a reason for not prescribing the other class when one of the following conditions was noted to be the reason for no ACEI or the reason for no ARB: angioedema, hyperkalemia, hypotension, renal artery stenosis, and worsening renal function/renal disease/dysfunction.

2. Since the time of last NQF endorsement (May 2007), the Heart Care measures team met with other topic teams within the Hospital Inpatient Quality Reporting Program (namely, children’s asthma and surgical care) to examine the medication constructs being used. The measure designs at that time automatically excluded patients with a documented contraindication to a medication or reason for not prescribing a medication from the measure, regardless of whether the medication ended up being prescribed. That type of design was resulting in a substantial amount of “false exclusions” from the measure. The decision was made to rearrange the measure such that patients who were prescribed the medication would remain in the measure (i.e., be included in the numerator) when a reason for not prescribing the medication was documented, effective with April 1, 2009 discharges. It is believed that the number of false exclusions has significantly decreased as a result.

3. Because the denominator exclusion “Patients with a documented reason for no ACEI and no ARB at discharge” allows for any physician/advance practice nurse/physician assistant/pharmacist-documented “other reason” for not prescribing ACEI or ARB at discharge to count as an exclusion, overuse of this exclusion has the potential for distorting performance rates. However, overall trends in measure numerator and denominator counts do not suggest obvious gaming of the measure. There has been no increasing trend in the use of this reason data element since the logical increase which resulted when abstraction guidelines were changed to allow for the documentation of a reason for not prescribing one class (either ACEI or ARB) to be considered implicit documentation of a reason for not prescribing the other class in the cases of angioedema, hyperkalemia, hypotension, renal artery stenosis, and worsening renal function/renal disease/dysfunction. Nevertheless, exclusion rates for this measure will continue to be monitored for consistency, from quarter to quarter.

4. The data elements used in this measure are closely tracked. Questions submitted by abstractors are recorded, and trends related to published abstraction guidelines and disagreements over measure inclusions and exclusions in general are discussed in-depth every 6 months. Revisions in measure specifications, including data element definitions, are made as issues surface (e.g., how to handle documentation of a hold on ACEI/ARB at discharge or a planned delay to start ACEI/ARB after discharge, what constitutes acceptable physician documentation of a reason for not prescribing ACEI/ARB). The frequency of questions pertaining to each data element are tracked by the Hospital Inpatient Quality Reporting Program QIOSC. Clearly the number of questions a data element receives is another indication of how difficult the specifications for the measure might be. Frequency reports are reviewed regularly, to help identify where issues in data element definitions may exist. Of note, in an August 2010 report run by the Hospital Inpatient Quality Reporting Program QIOSC, the number of questions about the abstraction of the four most unique data elements to this measure (shared with the AMI ACEI/ARB for LVSD measure), ACEI Prescribed at Discharge, ARB Prescribed at Discharge, LVSD, and Reason for No ACEI and No ARB at Discharge, amounted to 142, 16.7% of the total 848 Quest questions received for AMI and HF for that month. Lastly, CDAC validation reports (which compare hospital data to CDAC data) and internal CDAC abstractor accuracy reports are monitored, to ensure good quality data. In sum, issues which may surface in questions submitted by users and CDAC validation/accuracy reports will continue to be closely monitored to identify any additional problems, and revisions will be made if warranted.

4e. Data Collection Strategy/Implementation

4e.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data/missing data, timing/frequency of data collection, patient confidentiality, time/cost of data collection, other feasibility/implementation issues:

Both the change to allow for the documentation of a reason for not prescribing one class (either ACEI or ARB) to be considered implicit documentation of a reason for not prescribing the other class in the cases of
Angioedema, hyperkalemia, hypotension, renal artery stenosis, and worsening renal function for April 2007+ discharges and the reordering of the “medication prescribed” and “reason for no medication” specifications done for April 2009+ discharges (as described in section 4d.1) reduce abstraction burden. Abstractors no longer have to do an exhaustive search for acceptable reasons for not prescribing ACEI and/or ARB at discharge, saving valuable abstraction time. Additionally, the decision points relating to exclusions comfort measures only, clinical trial, and discharge disposition in the algorithms were rearranged for April 2008+ discharges. The new order enabled tool developers to program tools in such a way that the abstractor could skip abstraction of Comfort Measures Only (challenging data to abstract from some medical records) if the patient was transferred to another acute care hospital, left AMA, expired, or was discharged to hospice, saving important abstraction time as well.

4e.2 Costs to implement the measure (costs of data collection, fees associated with proprietary measures): Varies according to data collection method (use of vendor) and type of abstractor used to collect clinical data. We have not received feedback that this measure has caused undue burden to the facilities collecting data.

4e.3 Evidence for costs:
N/A

4e.4 Business case documentation: N/A

TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Feasibility?

<table>
<thead>
<tr>
<th>Rating</th>
<th>C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

Steering Committee: Overall, to what extent was the criterion, Feasibility, met?

Rationale:

RECOMMENDATION

(for NQF staff use) Check if measure is untested and only eligible for time-limited endorsement.

Steering Committee: Do you recommend for endorsement?

Comments:

Y N A

CONTACT INFORMATION

Co.1 Measure Steward (Intellectual Property Owner)
Co.1 Organization
Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, Maryland, 21244-1850

Co.2 Point of Contact
Kristie, Baus, RN, MS, kristie.baus@cms.hhs.gov, 410-786-8161-

Measure Developer if different from Measure Steward
Co.3 Organization
Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, Maryland, 21244-1850

Co.4 Point of Contact
Kristie, Baus, RN, MS, kristie.baus@cms.hhs.gov, 410-786-8161-

Co.5 Submitter If different from Measure Steward POC
Jo, DeBuhr, RN, BSN, broncosrule@att.net, 303-457-3195-, OFMQ

Co.6 Additional organizations that sponsored/participated in measure development
The Joint Commission
### ADDITIONAL INFORMATION

**Workgroup/Expert Panel involved in measure development**

Ad.1 Provide a list of sponsoring organizations and workgroup/panel members’ names and organizations.

Describe the members’ role in measure development.

This measure is reviewed and maintained by the Heart Care Technical Expert Panel. Quarterly teleconferences are held to discuss issues pertinent to this measure (and its specifications) and potential revisions. Current members:

- Frederick Masoudi, MD, MSPH Workgroup Chair: Denver Health Medical Center, University of Colorado at Denver and Health Sciences Center
- Don Casey, MD, MPh, MBA: VP Quality and Chief Medical Officer, Atlantic Health, Rep. of the American College of Physicians
- Elizabeth DeLong, PhD: Professor and Chair, Duke University, Biostatistics and Bioinformatics, Co-Director, Outcomes Research and Assessment
- Joseph Drozda, MD: Clinical Investigator, Mercy Health Research, Executive Committee Member, PCPI, Rep. of American Medical Association
- John P. Erwin, III: Professor of Medicine, Co-Director, Cardiovascular Fellowship Program, Hospital Champion, Acute Myocardial Infarction Quality Improvement, Scott and White Hospital and Clinic
- Kerri Fei: Senior Policy Analyst, Measure Development Operations, American Medical Association
- Susan Fitzgerald, RN, MS: Associate Director, Science and Quality, American College of Cardiology
- Gary Francis, MD: Professor of Medicine, University of Minnesota, Rep. of Heart Failure Society of America
- David C. Goff, MD, PhD: Professor and Chair, Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University School of Medicine
- Kathleen Grady, CNS: Administrative Director, Center for Heart Failure, Bluhm Cardiovascular Institute Division of Cardiothoracic Surgery, Northwestern Memorial Hospital
- Darryl Gray, MD: Medical Officer, Agency for Healthcare Research and Quality
- Lee Green, MD: Professor, University of Michigan Medical School
- Ed Havranek, MD: Professor of Medicine, Denver Health Medical Center, University of Colorado School of Medicine
- Paul A. Heidenreich: Assistant Professor of Medicine, Associate Professor by courtesy of Health Research and Policy at the VA Palo Alto Health Care System and CHP/PCOR Fellow
- Alice C. Jacobs, MD: Professor of Medicine, Director, Cardiac Cath Lab, Boston University Medical Center
- Marvin Konstam, MD: Director, Cardiovascular Center, Tufts Medical Center, Rep. of Heart Failure Society of America
- Harlan Krumholz, MD: Harold H. Hines, Jr. Professor of Medicine and Epidemiology and Public Health, Yale University School of Medicine
- Jerod Loeb, PhD: Executive Vice President, Quality Measurement & Research, The Joint Commission
- Ann [Hiniker] Loth, RN, MS, CNS: Certified Clinical Nurse Specialist, Mayo Foundation
- Joseph Messer, MD, MACC: Professor of Medicine, Rush University Medical Center, Rep. of American Medical Association
- Eric Peterson, MD, MPh: Professor of Medicine, Director Cardiovascular Research, Duke Clinical Research Institute, Duke University Medical Center
- Martha Radford, MD: Chief Quality Officer, Professor of Medicine, New York University School of Medicine
- Rose Marie Robertson, MD: Chief Science Officer, American Heart Association
- John Rumsfeld, MD, PhD, FACC, FAHA: Staff Cardiologist, Cardiovascular Outcomes Researcher, Denver Veterans Affairs Medical Center
- David Shahian, MD: Research Director, Center for Quality and Safety, Massachusetts General Hospital
- Melanie Shahriary, RN, BSN: Associate Director, Performance Measures and Data Standards, American College of Cardiology
- John Spertus, MD, MPh, FACC: Director of Cardiovascular Education and Outcomes Research, Mid America Heart Institute, University of Missouri
- Samantha Tierney: Senior Policy Analyst I, American Medical Association
- Gayle Whitman, PhD, RN, FAAN, FAHA: Sr Vice President, Office of Science Operations, American Heart Association
- Janet Wright, MD, FACC: Senior Vice President for Science and Quality, American College of Cardiology
- Contractor Staff: Dale Bratzler, DO, MPH: CEO, Principal Clinical Coordinator, Oklahoma Foundation for Medical Quality
- Jo DeBuhr, RN: Project Specialist, AMI/HF Inpatient Measures, Oklahoma Foundation for Medical Quality/Colorado Foundation for Medical Care
- Chris Leber, RN: Project Specialist, AMI/HF Inpatient Measures, Oklahoma Foundation for Medical
### Quality/Colorado Foundation for Medical Care
CMS Staff:
Kristie Baus, MS, RN: Government Task Leader, Centers for Medicare and Medicaid Services
David Nilasena, MD: Chief Medical Officer, Region VI, Centers for Medicare and Medicaid

| Ad.2 If adapted, provide name of original measure: | N/A |
| Ad.3-5 If adapted, provide original specifications URL or attachment |

### Measure Developer/Steward Updates and Ongoing Maintenance

| Ad.6 Year the measure was first released: | 1999 |
| Ad.7 Month and Year of most recent revision: | 10, 2010 |
| Ad.8 What is your frequency for review/update of this measure? | Every 6 months |
| Ad.9 When is the next scheduled review/update for this measure? | 07, 2011 |

| Ad.10 Copyright statement/disclaimers: |
| Ad.11 -13 Additional Information web page URL or attachment: |

| Date of Submission (MM/DD/YY): | 12/14/2010 |
Clinical care processes typically include multiple steps: assess → identify problem/potential problem → choose/plan intervention (with patient input) → provide intervention → evaluate impact on health status. If the measure focus is one step in such a multi-step process, the step with the greatest effect on the desired outcome should be selected as the focus of measurement. For example, although assessment of immunization status and recommending immunization are necessary steps, they are not sufficient to achieve the desired impact on health status - patients must be vaccinated to achieve immunity. This does not preclude consideration of measures of preventive screening interventions where there is a strong link with desired outcomes (e.g., mammography) or measures for multiple care processes that affect a single outcome.
Process of Care Performance Measures and Long-Term Outcomes in Patients Hospitalized With Heart Failure

Mark E. Patterson, MPH, PhD,* Adrian F. Hernandez, MD, MHS,†‡ Bradley G. Hammill, MS,* Gregg C. Fonarow, MD,§ Eric D. Peterson, MD, MPH,†‡ Kevin A. Schulman, MD,*‡ and Lesley H. Curtis, PhD*‡

Background: Recent efforts to improve care for patients hospitalized with heart failure have focused on process-based performance measures. Data supporting the link between current process measures and patient outcomes are sparse.

Objective: To examine the relationship between adherence to hospital-level process measures and long-term patient-level mortality and readmission.

Research Design: Analysis of data from a national clinical registry linked to outcome data from the Centers for Medicare and Medicaid Services (CMS).

Subjects: A total of 22,750 Medicare fee-for-service beneficiaries enrolled in the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure between March 2003 and December 2004.

Measures: Mortality at 1 year; cardiovascular readmission at 1 year; and adherence to hospital-level process measures, including discharge instructions, assessment of left ventricular function, prescription of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker at discharge, prescription of beta-blockers at discharge, and smoking cessation counseling for eligible patients.

Results: Hospital conformity rates ranged from 52% to 86% across the 5 process measures. Unadjusted overall 1-year mortality and cardiovascular readmission rates were 33% and 40%, respectively. In covariate-adjusted analyses, the CMS composite score was not associated with 1-year mortality (hazard ratio, 1.00; 95% confidence interval, 0.90–0.98; P = 0.004). Current CMS process measures were not independently associated with mortality, though prescription of beta-blockers at discharge was independently associated with lower mortality (hazard ratio, 0.94; 95% confidence interval, 0.90–0.98; P = 0.004).

Conclusion: Hospital process performance for heart failure as judged by current CMS measures is not associated with patient outcomes within 1 year of discharge, calling into question whether existing CMS metrics can accurately discriminate hospital quality of care for heart failure.

Key Words: heart failure, mortality, outcome and process assessment (health care), patient readmission

(210–216)

Supplemental variation exists in the provision of evidence-based, guideline-recommended care to patients hospitalized for heart failure in the United States. Recent efforts to improve the quality of care for these patients have focused on process-based performance measures. The Centers for Medicare and Medicaid Services (CMS) and the Joint Commission have designated 4 such process measures, and the American Heart Association (AHA) and the American College of Cardiology (ACC) have designated 5 discharge measures for heart failure (the 4 CMS measures plus anticoagulation for atrial fibrillation). Medicare and other payers use such measures in pay-for-performance programs and report the measures publicly on the Hospital Compare Web site to help patients select high-quality providers. Central to these programs is the implicit assumption that conformance with process measures improves patient outcomes. However, data supporting the process-outcome link are sparse.

Previous studies have examined associations between hospital-level performance and hospital-level outcomes and associations between patient-level adherence to process measures and patient-level outcomes. Hospital-level analyses have found no association between hospital-level adherence and 30-day mortality. Patient-level analyses suggest that adherence to certain process measures is strongly associated with 60- to 90-day postdischarge outcomes and that adherence to other process measures is not. These types of analyses do not address an important question from the
patient’s perspective: Are hospital-level performance measures important indicators of long-term patient outcomes? That is, is receiving care at a hospital with better conformity to recommended processes of care associated with better long-term outcomes for patients with heart failure?

Using data from the Organized Program to Initiate Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) registry linked to Medicare claims data, we examined the relationship between adherence to hospital-level process measures and patient-level mortality and readmission in the first year after discharge.

METHODS

Data Sources

Patients in this study were from the OPTIMIZE-HF registry, which has been described in detail previously. The registry was established to collect data regarding processes of care for patients hospitalized with heart failure. The 259 participating US hospitals enrolled 48,612 patients from March 1, 2003 to December 31, 2004, and used a case ascertainment approach similar to that used by the Joint Commission. Patients were eligible for the registry if (a) they presented with symptoms of heart failure during a hospitalization for which heart failure was the primary discharge diagnosis or (b) the primary reason for admission was an episode of worsening heart failure. The International Classification of Diseases, Ninth Revision, Clinical Modification codes used as enrollment criteria for OPTIMIZE-HF and case finding were identical to those used by CMS. Patients from all geographic regions of the United States were included and a variety of institutions participated, from community hospitals to large tertiary centers. Each center’s institutional review board or a central institutional review board approved the study protocol. Hospital staff used a Web-based case report form to record patient-level information, including demographic characteristics, comorbid conditions, vital signs, and drug therapy. Automatic electronic data checks prevented out-of-range entries and duplications. In addition, an audit of the database based on predetermined criteria verified data against source documents for a 5% random sample of the first 10,000 patients.

For this study, we merged patient data from the OPTIMIZE-HF registry with Medicare Part A inpatient claims, matching by date of birth, sex, hospital, and admission and discharge dates. Of 36,165 hospitalizations of patients aged 65 years or older, 29,301 (80.8%) were matched to Medicare claims, representing 25,901 distinct patients. We excluded 1218 patients who died before discharge, 1143 patients who were ineligible for any of the 4 process measures, and 790 patients in 88 hospitals with fewer than 25 eligible patients, a convention used in previous studies to improve the stability of process measure estimates. The final data set contained data on 22,750 patients from 150 hospitals. In addition to the overall cohort, we created 4 separate cohorts of patients who were eligible for each of the 4 process measures of interest. These cohorts included only data from hospitals with at least 25 eligible patients for a given process measure.

Process Measures

We analyzed a total of 5 process measures. These included the 4 process measures endorsed by CMS, the Joint Commission, and the ACC/AHA: (a) discharge instructions that address diet, exercise, medications, and relevant follow-up care for patients discharged to home; (b) assessment of left ventricular function; (c) prescription of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) at discharge to eligible patients with left ventricular systolic dysfunction without contraindications; and (d) smoking cessation counseling for patients who had smoked within 1 year of admission. In addition, we analyzed prescription of beta-blockers at discharge to eligible patients with left ventricular systolic dysfunction without contraindications. Although not endorsed by CMS, this process measure has been shown to be associated with improvement in short-term outcomes.

We constructed the performance measures by using the numerator and denominator definitions in the Joint Commission ORYX specifications; that is, we assessed use among eligible patients without documented contraindications, intolerance, or other physician documentation. Patients who died, were transferred to another acute care hospital, were discharged to hospice or a federal hospital, or left against medical advice were considered ineligible to receive any of the 5 processes of care. We summarized each process measure at the hospital level by dividing the number of patients for whom the process measure was documented by the number of patients eligible for the measure. In patient-level analyses, we applied hospital-level adherence rates uniformly to all patients within a given hospital; thus, the hospital-level rates can be considered continuous measures of hospital quality.

For each hospital, we constructed 2 overall scores. First, we constructed a composite score by dividing the total number of documented CMS-endorsed processes of care by the total number of opportunities to provide those processes of care, a score similar to that currently used in Medicare’s Hospital Compare as a basis for pay-for-performance programs for the 4 CMS measures. For example, a patient who received 2 of 4 processes of care for which she was eligible would contribute 2 to the numerator of the composite score and 4 to the denominator. The composite score indicates how often patients in a given hospital received the processes of care for which they were eligible. Second, we constructed a “defect-free” score to indicate the proportion of patients in the hospital who received all of the CMS-endorsed processes of care for which they were eligible. In this case, the patient from the previous example would contribute 0 to the numerator and 1 to the denominator, because she did not receive all of the processes of care.

The main outcome measure was mortality within 1 year after hospital discharge. We also analyzed cardiovascular readmission within 1 year after discharge. We obtained dates of death from CMS data through December 31, 2006. We defined cardiovascular readmission as the first subsequent inpatient admission for a cardiovascular reason as identified in Medicare Part A claims and defined by diagnosis related group codes 104 to 112, 115 to 118, 121 to 125, 127 to 145, 476, 514
to 518, 525 to 527, 535 to 536, and 547 to 558, excluding transfers or subsequent admissions for rehabilitation.

### Covariates

Baseline patient-level covariates from the OPTIMIZE-HF registry included age, race, history of acute myocardial infarction, diabetes mellitus, prior cerebrovascular disease, peripheral vascular disease, depression, hyperlipidemia, chronic obstructive pulmonary disease, and atrial arrhythmia; and mean serum creatinine, hemoglobin, systolic and diastolic blood pressure, and weight at admission. Between 1% and 6% of the patients had missing values for creatinine, hemoglobin, systolic and diastolic blood pressure, and weight. We imputed the mean values of the overall cohort for these missing values. From the CMS data, we calculated the total number of heart failure hospitalizations for each hospital and heart failure hospitalizations as a percentage of total hospital discharges and included these as hospital-level covariates.

### Statistical Analysis

We calculated frequencies and means for baseline demographic characteristics, comorbid conditions, and clinical characteristics for the full sample of 22,750 patients, and hospital-level volume and performance measures for the 150 hospitals. We present Kaplan-Meier estimates of unadjusted mortality, and we calculated unadjusted cardiovascular readmission rates using the cumulative incidence function. In the primary analysis, we examined the relationship between hospital-level adherence and patient-level outcomes. Specifically, we used Cox proportional hazards models to estimate the unadjusted and adjusted effects of each hospital-level process measure on mortality and cardiovascular readmission. The multivariable models included the patient-level and hospital-level covariates described above. To account for the clustering of patients within hospitals, we calculated robust standard errors. We performed 2 sensitivity analyses. First, we relaxed the requirement for eligible patients per hospital from 25 to 10. Second, to assess the need for random effects, we modeled the mortality end point using a generalized linear model with a logit link and binomial variance function and specified site-level random intercepts.

To address the question of whether higher-performing hospitals have lower 1-year risk-adjusted mortality rates compared with lower-performing hospitals, we estimated the relationship between hospital-level process measures and hospital-level risk-adjusted outcomes using a bootstrap approach. For each patient, we first calculated predicted probabilities of mortality and cardiovascular readmission, based on regression models that included the baseline patient-level covariates listed above. We then drew 1000 samples (with replacement) of 22,750 patients from the data used in the main analysis. For each sample, we calculated the hospital-level conformity rates and hospital-level risk-adjusted outcome rates. Conformity rates were calculated as previously described. Risk-adjusted outcome rates were calculated by dividing the observed outcome rate by the expected outcome rate and multiplying this quantity by the observed 1-year outcome rate in the overall sample. In each sample, we regressed these hospital-level risk-adjusted mortality and readmission rates on each of the hospital-level process measures. For each outcome, the mean of all parameter estimates is reported for each process measure. To address statistical significance, we provide the 95th bootstrap percentile interval. We used SAS software version 9.1 (SAS Institute Inc, Cary, NC) for all analyses.

### RESULTS

The mean age of the overall cohort was 79 years, 44% were men, and 83% were white. Approximately one-quarter of the patients had a history of acute myocardial infarction or non-insulin-dependent diabetes mellitus, and almost one-third had a history of hyperlipidemia or chronic obstructive pulmonary disease (Table 1). Unadjusted overall 1-year mortality and cardiovascular readmission rates were 33% and 40%, respectively.

The median number of patients with heart failure treated annually at each hospital was 227 (interquartile range, 136–381). Mean hospital-level adherence rates for individual process measures varied considerably. On average, hospitals assessed left ventricular function in 86% of eligible patients but provided discharge instructions to only 52% of eligible patients. The mean hospital-level composite score, which indicates the proportion of CMS-endorsed care processes that were correctly provided, was 72%. The defect-free measure, which indicates the proportion of patients receiving all of the CMS-endorsed processes of care for which they were eligible, was 51% (Table 2). When applied uniformly to all patients in a

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean ± SD, yr</td>
<td>79.4 ± 7.8</td>
</tr>
<tr>
<td>Male sex, number (%)</td>
<td>9986 (43.9)</td>
</tr>
<tr>
<td>Race, number (%)</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>2451 (10.8)</td>
</tr>
<tr>
<td>White</td>
<td>18821 (82.7)</td>
</tr>
<tr>
<td>Other</td>
<td>1478 (6.5)</td>
</tr>
<tr>
<td>Medical history, number (%)</td>
<td></td>
</tr>
<tr>
<td>Atrial arrhythmia</td>
<td>8189 (36.0)</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>7577 (33.3)</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>6492 (28.5)</td>
</tr>
<tr>
<td>Non-insulin-dependent diabetes mellitus</td>
<td>5618 (24.7)</td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>5183 (22.8)</td>
</tr>
<tr>
<td>Prior cerebrovascular accident or transient ischemic attack</td>
<td>3930 (17.3)</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>3390 (14.9)</td>
</tr>
<tr>
<td>Insulin-dependent diabetes mellitus</td>
<td>3371 (14.8)</td>
</tr>
<tr>
<td>Depression</td>
<td>2346 (10.3)</td>
</tr>
<tr>
<td>Clinical characteristics at admission</td>
<td></td>
</tr>
<tr>
<td>Serum creatinine, mean ± SD, mg/dL</td>
<td>1.6 ± 1.2</td>
</tr>
<tr>
<td>Hemoglobin, mean ± SD, g/dL</td>
<td>12.0 ± 1.9</td>
</tr>
<tr>
<td>Systolic blood pressure, mean ± SD, mm Hg</td>
<td>143.3 ± 31.5</td>
</tr>
<tr>
<td>Diastolic blood pressure, mean ± SD, mm Hg</td>
<td>74.6 ± 17.9</td>
</tr>
<tr>
<td>Weight, median (interquartile range), kg</td>
<td>76.1 (63.4–88.9)</td>
</tr>
</tbody>
</table>
defect-free score* 150 152 (133) 79 (77) 0.51 (0.22) 0.51 (0.32–0.70)

Composite score* 150 320 (281) 232 (203) 0.72 (0.15) 0.73 (0.62–0.84)

Beta-blocker at discharge 101 67 (42) 54 (35) 0.81 (0.11) 0.82 (0.74–0.89)

Smoking cessation counseling 25 40 (14) 24 (12) 0.61 (0.24) 0.59 (0.46–0.83)

ACE inhibitor or ARB at discharge 97 62 (38) 49 (32) 0.80 (0.11) 0.81 (0.70–0.89)

Assessment of left ventricular function 150 149 (129) 127 (107) 0.86 (0.11) 0.88 (0.80–0.95)

Discharge instructions 139 121 (103) 65 (67) 0.52 (0.29) 0.55 (0.28–0.77)

© 2010 Lippincott Williams & Wilkins

www.lww-medicalcare.com

Cardiovascular readmission at 1 year.

The risk of death associated with the conformity to the ACE inhibitor/ARB measure trended toward a lower adjusted mortality rate (hazard ratio, 0.96; 95% confidence interval, 0.92–1.00; P = 0.07). Associations between all of the process measures and cardiovascular readmission were unchanged in a separate sensitivity analysis, we assessed the need for random effects by fitting a hierarchical model for the mortality end point. The results corresponded almost exactly with those from the proportional hazards model with robust standard errors (Table A1, online only, Supplemental Digital Content 1, available at: http://links.lww.com/MLR/A64).

Table 4 shows the results of the bootstrap analyses. None of the hospital-level individual process measure adherence rates or composite scores was found to be significantly associated with hospital-level risk-adjusted outcomes. Effect sizes were again found to be small.

CONCLUSIONS

In this analysis of 22,750 Medicare beneficiaries hospitalized with heart failure at 150 US hospitals, we found...
substantial variation in hospital adherence to the 4 CMS process measures. Yet, with the exception of the positive association between hospital-level conformity to the assessment of left ventricular function and cardiovascular readmission, there were no associations between the CMS hospital performance measures or the composite measures and patient-level mortality or cardiovascular readmission rates at 1 year. However, we did find a significant association between hospital-level adherence to prescription of beta-blockers at discharge and lower mortality at 1 year. To explore these associations with risk-adjusted hospital-level outcomes, we conducted bootstrap analyses and found the results to be generally consistent with the primary analysis.

These findings are generally consistent with a previous analysis examining patient-level predictors and outcomes of 5791 patients from the 91 hospitals who participated in OPTIMIZE-HF. In that study, only conformity with a measure for prescription of a beta-blocker for left ventricular systolic dysfunction was significantly associated with a lower risk of 60- to 90-day mortality after propensity adjustment and risk adjustment. The findings are also consistent with a study using an administrative data source to examine associations between hospital-level processes of care and hospital-level outcomes in 3657 acute care hospitals, which found that assessment of left ventricular function and prescription of an ACE inhibitor at discharge were not significantly associated with improved survival at 1 year. The absolute risk reduction in risk-adjusted mortality between hospitals performing in the 25th percentile compared with those performing in the 75th percentile was 0.002 ($P = 0.05$) for assessment of left ventricular function, $-0.003 (P = 0.04)$ for ACE inhibitor use, and $0.002 (P = 0.08)$ for 1-year mortality. In contrast, a study of 2958 patients drawn from a 20-hospital health care system in a single community reported an association between CMS process measures at discharge and 1-year survival, though multiple known confounders were not included in the multivariable models and nurse case managers continued to be involved in the care of patients after discharge.

The present analysis expands upon findings from previous studies in 2 key ways. First, this study links Medicare administrative data to a detailed clinical source to allow for both longitudinal outcome assessment and rigorous risk adjustment. Thus, we were able to determine whether CMS process measures for heart failure had measurable effects up to 1 year after discharge in a broad cohort of patients from all regions of the United States. In addition, the analysis examines how overall hospital adherence levels are related to patient-level mortality and cardiovascular readmission, thereby addressing the question of whether patients who are treated at hospitals that score higher on process measures have better outcomes. This analytic approach addresses whether receiving care at a hospital with better conformity to recommended processes of care is associated with improvements in long-term outcomes for patients with heart failure.

Previous research from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines) has also addressed the associations between hospital-level predictors and patient-level outcomes, but for patients hospitalized with acute coronary syndromes. Although hospital profit status and the presence of an inpatient cardiology service were not significantly associated with inpatient outcomes, hospital participation in clinical trials was significantly related to patient-level mortality.

There are several potential explanations for the lack of associations in this study. First, the processes of care selected for the performance measures may truly not be associated with outcomes. Evidence of associations between discharge instructions, assessment of left ventricular function, and smoking cessation counseling are based on expert opinion rather than randomized clinical trials. Furthermore, outcomes after hospital discharge likely reflect a combination of many domains of care and may be dominated by postdischarge care processes, frequency of follow-up, and the underlying disease process. For example, being discharged with an ACE inhibitor or ARB does not ensure that a patient will remain on therapy or that an effective dose has been prescribed, nor does it ensure that the clinical effects will be observable within 1 year.

## Table 4. Relationship Between Hospital-Level Process Measures and Hospital-Level Risk-Adjusted Outcomes at 1 Year

<table>
<thead>
<tr>
<th>Measure</th>
<th>Absolute Percentage Change in</th>
<th>Outcome Due to 10% Change in</th>
<th>Process Measure (95% Bootstrap Percentile Interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mortality</td>
<td>Cardiovascular Readmission</td>
<td></td>
</tr>
<tr>
<td>Discharge instructions</td>
<td>0.0 (−0.3 to 0.3)</td>
<td>−0.2 (−0.4 to 0.1)</td>
<td></td>
</tr>
<tr>
<td>Assessment of left ventricular function</td>
<td>−0.2 (−1.1 to 0.7)</td>
<td>0.0 (−0.8 to 0.8)</td>
<td></td>
</tr>
<tr>
<td>ACE inhibitor or ARB at discharge</td>
<td>0.1 (−0.7 to 0.8)</td>
<td>0.0 (−0.6 to 0.7)</td>
<td></td>
</tr>
<tr>
<td>Smoking cessation counseling</td>
<td>−0.2 (−0.8 to 0.3)</td>
<td>0.2 (−0.2 to 0.6)</td>
<td></td>
</tr>
<tr>
<td>Beta-blocker at discharge</td>
<td>−0.3 (−1.1 to 0.4)</td>
<td>−0.4 (−1.1 to 0.2)</td>
<td></td>
</tr>
<tr>
<td>Composite score*</td>
<td>0.1 (−0.5 to 0.7)</td>
<td>−0.1 (−0.6 to 0.3)</td>
<td></td>
</tr>
<tr>
<td>Defect-free score*</td>
<td>0.2 (−0.3 to 0.6)</td>
<td>−0.1 (−0.4 to 0.2)</td>
<td></td>
</tr>
</tbody>
</table>

*Scores include CMS-endorsed measures only (ie, discharge instructions, assessment of left ventricular function, ACE inhibitor or ARB at discharge, and smoking cessation counseling).
examining effects of system-level exposures on individual-level outcomes may be limited by the inability to control for unobserved system-level characteristics, which could result in null associations.

Other findings in this study warrant comment. First, we found a small but significant association between assessment of left ventricular function and greater risk of cardiovascular readmission. The reason for this finding is unclear; we suspect it may reflect residual confounding in which patients who are sicker in ways we did not measure may have been more likely to undergo assessment of left ventricular function and be hospitalized as compared with healthier patients. Second, the demographic characteristics of the sample are comparable to another study estimating trends in mortality among hospitalized Medicare beneficiaries with heart failure,21 providing some evidence of how the results of the current study are generalizable to Medicare fee-for-service beneficiaries. Third, the high mortality and cardiovascular readmission rates found in this patient population indicate that this is a high-risk population that would likely benefit from improved process measure conformity in measures with a strong process-outcome link.

Our study has some limitations. First, the process-outcome association may be confounded by socioeconomic factors or other unmeasured confounders related to both health status and hospital adherence level. Second, to the extent that Medicare beneficiaries enrolled in OPTIMIZE-HF are not representative of all Medicare beneficiaries with heart failure, the results may not be generalizable. Evidence suggests, however, that Medicare beneficiaries enrolled in OPTIMIZE-HF are similar to Medicare fee-for-service beneficiaries hospitalized with heart failure in terms of baseline characteristics, survival, and all-cause readmission.22 Third, the generalizability of the results may be further limited if participating hospitals differ from nonparticipating hospitals in ways not reflected inpatient demographic characteristics, core measures, or postdischarge outcomes. Fourth, patient eligibility for a performance measure was based on documentation in the medical record, which may not always be accurate. For example, some patients may have had undocumented contraindications or intolerances, leading to an overestimation of the number of patients eligible for the performance measure. Finally, the cross-sectional nature of the data did not allow us to assess changes in performance measure conformity and clinical outcomes over time.

Performance measures are used for public reporting of the quality of cardiovascular care at the hospital level, affecting financial payments to medical centers and individual physicians. Thus, it is essential that measures be prioritized to include those that are known to be closely associated with patient outcomes. Given the lack of associations between individual measures and a composite measure and postdischarge clinical outcomes, the use of the CMS heart failure performance measures in their current form in pay-for-performance programs may not be the most efficacious way to assess and reward quality. Although clearly stated methods have been used to develop and implement heart failure performance measures, these measures are not fulfilling their stated purpose. Consequently, additional measures with stronger process-outcome links after hospital discharge should be considered. If a documentation process at the hospital does not accurately capture the most important elements of care provided, it may be unreasonable to expect that incentives for these process measures would improve outcomes.

To our knowledge, this analysis is the first to examine how overall hospital conformity to the 4 current CMS heart failure-specific process measures is associated with individual-level, long-term outcomes in a broad cohort of patients from all regions of the United States. To build upon these results, future research is needed to refine how performance measures are created and selected. Consideration should be given to prospective validation and testing of measures, rather than the selection of measures by expert panels. Before implementing pay-for-performance broadly across all systems, the limitations of current performance measures and the differences in measure reliability across disease types, provider settings, and patient populations need to be better recognized. In addition, a minimally important difference needs to be defined before policy makers decide to implement new process measures, especially given the small effect sizes.23 The small effect sizes may not be sufficient to justify broad policy changes, especially if the cost of such changes would not justify changes that were not clinically significant. It is essential that new process of care measures for heart failure be developed and implemented so that the quality of care can be more accurately measured and outcomes of this high-risk patient population can be improved.

REFERENCES

10. Fonarow GC, Abraham WT, Albert NM, et al. Prospective evaluation of


